Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
Trend | Peers | Company |
---|---|---|
Is return on equity increasing? | Yes | No |
Is net profit margin increasing? | Yes | Yes |
Is asset turnover increasing? | Yes | Yes |
Is equity multiplier increasing? | No | No |
Competitors Used |
---|
AstraZeneca PLC |
Genomma Lab Internacional, S.A.B. de C.V. |
Merck KGaA |
H. Lundbeck A/S |
Merck & Co., Inc. |
Return on Equity Benchmarks | ||||||||
Comparable Companies | ||||||||
AZN | LAB B | 14 | 0ND5 | 0QAH | GLAX.F | |||
Return On Equity | ||||||||
Latest Twelve Months | 20% | 21% | 10% | 14% | 39% | 23% | ||
Fiscal Year - 1 | 16% | 11% | 11% | 11% | 1% | 41% | ||
Fiscal Year - 2 | 9% | 14% | 14% | 10% | 34% | 35% | ||
Fiscal Year - 3 | 0% | 14% | 16% | 7% | 39% | 22% | ||
Fiscal Year - 4 | 22% | 17% | 11% | 9% | 18% | 37% | ||
Fiscal Year - 5 | 10% | 10% | 7% | 15% | 22% | 61% | ||
Average | 13% | 14% | 12% | 11% | 25% | 37% | ||
Median | 13% | 14% | 11% | 10% | 28% | 36% | ||
Benchmarks | Ticker | |||||||
AstraZeneca PLC | LSE:AZN | |||||||
Genomma Lab Internacional, S.A.B. de C.V. | BMV:LABB | |||||||
Merck KGaA | LSE:0O14 | |||||||
H. Lundbeck A/S | LSE:0ND5 | |||||||
Merck & Co., Inc. | LSE:0QAH |
Financial Performance | ||||||||
Comparable Companies | ||||||||
(in millions) | AZN | LAB B | Jan-00 | 0ND5 | 0QAH | GLAX.F | ||
Latest Fiscal Year | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
LTM Period | Mar-25 | Mar-25 | Mar-25 | Mar-25 | Mar-25 | Mar-25 | ||
Revenues | ||||||||
Latest Twelve Months | 54,982 | 18,816 | 21,316 | 22,951 | 63,922 | 31,529 | ||
Fiscal Year | 54,073 | 18,607 | 21,156 | 22,004 | 64,168 | 31,376 | ||
Fiscal Year - 1 | 45,811 | 16,467 | 20,993 | 19,912 | 60,115 | 30,328 | ||
Fiscal Year - 2 | 44,351 | 16,820 | 22,232 | 18,246 | 59,283 | 29,324 | ||
Fiscal Year - 3 | 37,417 | 15,487 | 19,687 | 16,299 | 48,704 | 24,696 | ||
Fiscal Year - 4 | 26,617 | 13,870 | 17,534 | 17,672 | 41,518 | 24,354 | ||
Fiscal Year - 5 | 24,384 | 12,713 | 16,152 | 17,036 | 39,121 | 33,754 | ||
Net Income | ||||||||
Latest Twelve Months | 7,772 | 2,158 | 2,818 | 3,289 | 17,434 | 3,153 | ||
Fiscal Year | 7,035 | 2,091 | 2,777 | 3,143 | 17,117 | 2,575 | ||
Fiscal Year - 1 | 5,955 | 1,085 | 2,824 | 2,290 | 365 | 4,928 | ||
Fiscal Year - 2 | 3,288 | 1,366 | 3,326 | 1,916 | 14,519 | 4,461 | ||
Fiscal Year - 3 | 112 | 1,308 | 3,055 | 1,318 | 12,345 | 3,316 | ||
Fiscal Year - 4 | 3,196 | 1,404 | 1,987 | 1,581 | 4,519 | 4,873 | ||
Fiscal Year - 5 | 1,335 | 750 | 1,292 | 2,313 | 5,690 | 4,645 | ||
Total Assets | ||||||||
Latest Fiscal Quarter Prior | 102,293 | 21,312 | 49,504 | 37,852 | 105,849 | 58,511 | ||
Latest Fiscal Quarter | 106,253 | 24,080 | 49,373 | 54,219 | 115,122 | 60,705 | ||
Fiscal Year | 104,035 | 23,018 | 51,567 | 56,976 | 117,106 | 59,463 | ||
Fiscal Year - 1 | 101,119 | 20,697 | 48,495 | 37,407 | 106,675 | 59,005 | ||
Fiscal Year - 2 | 96,483 | 21,607 | 48,535 | 37,452 | 109,160 | 60,146 | ||
Fiscal Year - 3 | 105,363 | 21,543 | 45,362 | 34,653 | 105,694 | 79,103 | ||
Fiscal Year - 4 | 66,729 | 21,341 | 41,796 | 36,029 | 91,588 | 80,431 | ||
Fiscal Year - 5 | 61,377 | 18,530 | 43,808 | 38,133 | 84,397 | 79,692 | ||
Fiscal Year - 6 | 60,651 | 18,077 | 36,888 | 23,011 | 82,637 | 58,066 | ||
Common Equity | ||||||||
Latest Fiscal Quarter Prior | 37,445 | 9,774 | 27,996 | 22,435 | 40,364 | 13,840 | ||
Latest Fiscal Quarter | 41,039 | 11,109 | 29,823 | 24,571 | 48,335 | 14,157 | ||
Fiscal Year | 40,786 | 10,885 | 29,912 | 25,010 | 46,313 | 13,671 | ||
Fiscal Year - 1 | 39,143 | 9,383 | 26,680 | 22,045 | 37,581 | 13,347 | ||
Fiscal Year - 2 | 37,037 | 10,153 | 25,927 | 20,779 | 45,991 | 10,598 | ||
Fiscal Year - 3 | 39,268 | 10,072 | 21,338 | 18,279 | 38,184 | 15,055 | ||
Fiscal Year - 4 | 15,622 | 8,842 | 16,946 | 16,973 | 25,317 | 14,587 | ||
Fiscal Year - 5 | 13,127 | 7,249 | 17,841 | 16,782 | 25,907 | 11,405 | ||
Fiscal Year - 6 | 12,468 | 7,428 | 17,200 | 14,251 | 26,701 | 3,781 |